Scott V. Joy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Scott V. Joy has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Ann C Scates
Ann C Scates PharmD, Clinical Pharmacist and Drug Information Specialist, Department of Pharmacy, Duke University Hospital
2 shared publicationsC.A. Taulien
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27705-0493, USA
1 shared publicationChristina A Taulien
Christina A Taulien MD, Resident in Internal Medicine, Department of Medicine, Duke University Medical Center
1 shared publicationJason A Goebel
Jason A Goebel MD, Resident in Internal Medicine, Department of Medicine, Duke University Medical Center
1 shared publicationMichael J Cooney
Michael J Cooney MD, Assistant Professor of Ophthalmology, Department of Ophthalmology, Duke University Medical Center
1 shared publicationMoahad Dar
Moahad Dar MD, Fellow in Endocrinology, Department of Medicine, Duke University Medical Center
1 shared publication
Latest Publications
- 1 May 2008
- Published by SAGE Publications in The Diabetes Educator
- Vol. 34 (3_suppl) , 54S-59S
Clinical Pearls and Strategies to Optimize Patient Outcomes
Increasing evidence suggests that a large proportion of patients with type 2 diabetes do not meet glycemic targets. Early diagnosis, realistic goal setting, improved patient adherence, and a better understanding of the pharmacotherapeutic treatment options are crucial to improving diabetes treatment outcomes in the United States. There are many reasons why patients do not achieve glycemic control. Barriers faced by clinicians, such as clinical inertia, lack of education time, and inappropriate use and titration of medications, need to be overcome to improve patient care. At the same time, patients are challenged by lifestyle management, lack of understanding of therapeutic options, and failing to see themselves as partners in their own care. Successful diabetes management programs incorporate several key features, including proactive reminders, consistent follow-up procedures, and use of clinical information systems to improve patient adherence and overall quality of care. Both clinicians and patients face barriers to advancing to injectable medications. Patients' attitudes may include fears of injections, technical challenges, and “punishment” for “failing” treatment. Clinicians have concerns about inadequate resources to address the needs of patients, patient nonadherence, and hypoglycemic events associated with certain injectable medications. Many of the strategies to overcome these barriers are reviewed.
- 1 May 2008
- Published by SAGE Publications in The Diabetes Educator
- Vol. 34 (3_suppl) , 54S-59S
Clinical Pearls and Strategies to Optimize Patient Outcomes
Increasing evidence suggests that a large proportion of patients with type 2 diabetes do not meet glycemic targets. Early diagnosis, realistic goal setting, improved patient adherence, and a better understanding of the pharmacotherapeutic treatment options are crucial to improving diabetes treatment outcomes in the United States. There are many reasons why patients do not achieve glycemic control. Barriers faced by clinicians, such as clinical inertia, lack of education time, and inappropriate use and titration of medications, need to be overcome to improve patient care. At the same time, patients are challenged by lifestyle management, lack of understanding of therapeutic options, and failing to see themselves as partners in their own care. Successful diabetes management programs incorporate several key features, including proactive reminders, consistent follow-up procedures, and use of clinical information systems to improve patient adherence and overall quality of care. Both clinicians and patients face barriers to advancing to injectable medications. Patients' attitudes may include fears of injections, technical challenges, and “punishment” for “failing” treatment. Clinicians have concerns about inadequate resources to address the needs of patients, patient nonadherence, and hypoglycemic events associated with certain injectable medications. Many of the strategies to overcome these barriers are reviewed.
- 1 January 2006
- Published by Portico in Drugs of Today
- Vol. 42 (9) , 577-585
Ruboxistaurin
Ruboxistaurin is a potent and specific inhibitor of the beta isoform of protein kinase C. Overactivation of protein kinase C has been demonstrated in patients with type 2 diabetes, and is postulated to play a major role in the pathogenesis of diabetic microvascular complications, which include diabetic retinopathy, neuropathy and nephropathy. The role of protein kinase C in promoting tissue injury in patients with diabetes, and the pharmacologic and clinical studies illustrating the potential of ruboxistaurin to reduce the burden of diabetic microvascular complications will be discussed in this article (c) 2006 Prous Science. All rights reserved.
- 1 January 2006
- Published by Portico in Drugs of Today
- Vol. 42 (9) , 577-585
Ruboxistaurin
Ruboxistaurin is a potent and specific inhibitor of the beta isoform of protein kinase C. Overactivation of protein kinase C has been demonstrated in patients with type 2 diabetes, and is postulated to play a major role in the pathogenesis of diabetic microvascular complications, which include diabetic retinopathy, neuropathy and nephropathy. The role of protein kinase C in promoting tissue injury in patients with diabetes, and the pharmacologic and clinical studies illustrating the potential of ruboxistaurin to reduce the burden of diabetic microvascular complications will be discussed in this article (c) 2006 Prous Science. All rights reserved.
- 1 October 2005
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 39 (10) , 1693-1699
Ruboxistaurin, a Protein Kinase C β Inhibitor, as an Emerging Treatment for Diabetes Microvascular Complications
OBJECTIVE: To review current clinical data regarding the pharmacologic actions of ruboxistaurin (LY333531) mesylate, an inhibitor of protein kinase C (PKC) β, and its role to potentially reduce the development and/or the progression of diabetic microvascular complications. DATA SOURCES: Primary literature was obtained via a MEDLINE search (1966–August 2004) and through review of pertinent abstracts and presentations at major medical meetings. STUDY SELECTION AND DATA EXTRACTION: Literature relevant to PKC physiology, the pharmacokinetics of ruboxistaurin, and data evaluating the use of ruboxistaurin in treating diabetic microvascular complications in human and relevant animal models was reviewed. DATA SYNTHESIS: PKC is part of a group of intracellular signaling molecules activated in response to various specific hormonal, neuronal, and growth factor stimuli. Hyperglycemia leads to PKC β 1 and 2 isoform activation, which experimentally has been shown to contribute to the development and progression of diabetic microvascular complications (retinopathy, nephropathy, neuropathy) through various biochemical mechanisms. Animal and/or human studies using ruboxistaurin mesylate, a novel, highly selective inhibitor of PKC β, have shown delay in the progression and, in some cases, reversal of diabetic retinopathy, nephropathy, and neuropathy. CONCLUSIONS: Ruboxistaurin mesylate, by inhibiting excessive activation of certain PKC isoforms, has the potential to reduce the burden of microvascular complications for patients with diabetes.
- 1 October 2005
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 39 (10) , 1693-1699
Ruboxistaurin, a Protein Kinase C β Inhibitor, as an Emerging Treatment for Diabetes Microvascular Complications
OBJECTIVE: To review current clinical data regarding the pharmacologic actions of ruboxistaurin (LY333531) mesylate, an inhibitor of protein kinase C (PKC) β, and its role to potentially reduce the development and/or the progression of diabetic microvascular complications. DATA SOURCES: Primary literature was obtained via a MEDLINE search (1966–August 2004) and through review of pertinent abstracts and presentations at major medical meetings. STUDY SELECTION AND DATA EXTRACTION: Literature relevant to PKC physiology, the pharmacokinetics of ruboxistaurin, and data evaluating the use of ruboxistaurin in treating diabetic microvascular complications in human and relevant animal models was reviewed. DATA SYNTHESIS: PKC is part of a group of intracellular signaling molecules activated in response to various specific hormonal, neuronal, and growth factor stimuli. Hyperglycemia leads to PKC β 1 and 2 isoform activation, which experimentally has been shown to contribute to the development and progression of diabetic microvascular complications (retinopathy, nephropathy, neuropathy) through various biochemical mechanisms. Animal and/or human studies using ruboxistaurin mesylate, a novel, highly selective inhibitor of PKC β, have shown delay in the progression and, in some cases, reversal of diabetic retinopathy, nephropathy, and neuropathy. CONCLUSIONS: Ruboxistaurin mesylate, by inhibiting excessive activation of certain PKC isoforms, has the potential to reduce the burden of microvascular complications for patients with diabetes.
- 1 January 2005
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 39 (1) , 110-118
Incretin Mimetics as Emerging Treatments for Type 2 Diabetes
OBJECTIVE: To review the physiology, pharmacology, and clinical efficacy of glucagon-like peptide (GLP-1) and the incretin mimetics exenatide and liraglutide in clinical studies. DATA SOURCES: Primary literature obtained via MEDLINE (1966–April 2004) and International Pharmaceutical Abstracts (1970–April 2004) searches; abstracts obtained from meeting sources and manufacturers. STUDY SELECTION AND DATA EXTRACTION: All English-language studies and abstracts evaluating GLP-1, exenatide, and liraglutide in the treatment of patients with type 2 diabetes were reviewed. Data from animal studies were also included if human data were not available. Primary and review articles related to the physiology, development, and evaluation of GLP-1s were reviewed. DATA SYNTHESIS: GLP-1, exenatide (exendin-4, AC2993), and liraglutide (NN2211) are incretin mimetics that have been shown in human studies to be an effective treatment to improve glycemic control in patients with type 2 diabetes. Mechanisms by which these compounds improve glycemic control include enhancing glucose-dependent pancreatic secretion of insulin in response to nutrient intake, inhibiting glucagon secretion, delaying gastric emptying, and promoting early satiety. GLP-1 has been shown to promote pancreatic progenitor cell differentiation and improve β-cell function and lifespan. Reported adverse effects of exenatide and liraglutide include nausea, vomiting, and transient headache, as well as increased risk of hypoglycemia when used with sulfonylureas. CONCLUSIONS: Clinical studies show that GLP-1, exenatide, and liraglutide improve glycemic control for patients with type 2 diabetes through unique mechanisms not available with current pharmaceutical products. Ongoing Phase III studies will help to further position these compounds as treatment options for patients with type 2 diabetes.
- 1 January 2005
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 39 (1) , 110-118
Incretin Mimetics as Emerging Treatments for Type 2 Diabetes
OBJECTIVE: To review the physiology, pharmacology, and clinical efficacy of glucagon-like peptide (GLP-1) and the incretin mimetics exenatide and liraglutide in clinical studies. DATA SOURCES: Primary literature obtained via MEDLINE (1966–April 2004) and International Pharmaceutical Abstracts (1970–April 2004) searches; abstracts obtained from meeting sources and manufacturers. STUDY SELECTION AND DATA EXTRACTION: All English-language studies and abstracts evaluating GLP-1, exenatide, and liraglutide in the treatment of patients with type 2 diabetes were reviewed. Data from animal studies were also included if human data were not available. Primary and review articles related to the physiology, development, and evaluation of GLP-1s were reviewed. DATA SYNTHESIS: GLP-1, exenatide (exendin-4, AC2993), and liraglutide (NN2211) are incretin mimetics that have been shown in human studies to be an effective treatment to improve glycemic control in patients with type 2 diabetes. Mechanisms by which these compounds improve glycemic control include enhancing glucose-dependent pancreatic secretion of insulin in response to nutrient intake, inhibiting glucagon secretion, delaying gastric emptying, and promoting early satiety. GLP-1 has been shown to promote pancreatic progenitor cell differentiation and improve β-cell function and lifespan. Reported adverse effects of exenatide and liraglutide include nausea, vomiting, and transient headache, as well as increased risk of hypoglycemia when used with sulfonylureas. CONCLUSIONS: Clinical studies show that GLP-1, exenatide, and liraglutide improve glycemic control for patients with type 2 diabetes through unique mechanisms not available with current pharmaceutical products. Ongoing Phase III studies will help to further position these compounds as treatment options for patients with type 2 diabetes.